Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...
Hosted on MSN5d
NeoGenomics (NASDAQ:NEO) Misses Q4 Sales TargetsOncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) in Q4 CY2024, but sales rose 10.6% year on year to $172 ...
Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
Hosted on MSN5d
Why NeoGenomics (NEO) Shares Are Trading Lower TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...
Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below provides a snapshot of ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback